SZSE:002880 (China)
Â
Class A
Â¥
28.10
(+1.08%)
Dec 27
Business Description
Shenzhen Weiguang Biological Products Co Ltd
ISIN : CNE100002Q58
Share Class Description:
SZSE:002880: Class ACompare
Compare
Traded in other countries / regions
002880.China IPO Date
2017-06-16Description
Shenzhen Weiguang Biological Products Co Ltd is the pharmaceutical company. It is mainly engaged in the research and development, production and sales of blood products. The company's products portfolio includes human albumin, intravenous immunoglobulin (pH4), lyophilized human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus Human immunoglobulin, histamine human immunoglobulin, human fibrinogen, a total of 21 varieties of 21 specifications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | 2.3 | |||||
| Interest Coverage | 14.88 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.45 | |||||
| Beneish M-Score | -1.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.1 | |||||
| 3-Year EBITDA Growth Rate | -2.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.5 | |||||
| 3-Year FCF Growth Rate | -24.5 | |||||
| 3-Year Book Growth Rate | 7.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.66 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.08 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.96 | |||||
| 9-Day RSI | 40.91 | |||||
| 14-Day RSI | 43.98 | |||||
| 6-1 Month Momentum % | 3.83 | |||||
| 12-1 Month Momentum % | -18.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.89 | |||||
| Quick Ratio | 1.78 | |||||
| Cash Ratio | 0.69 | |||||
| Days Inventory | 381.95 | |||||
| Days Sales Outstanding | 24.39 | |||||
| Days Payable | 32.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.71 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| 3-Year Dividend Growth Rate | 9.6 | |||||
| Forward Dividend Yield % | 1.42 | |||||
| 5-Year Yield-on-Cost % | 0.74 | |||||
| Shareholder Yield % | -1.04 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.64 | |||||
| Operating Margin % | 25.71 | |||||
| Net Margin % | 21.43 | |||||
| FCF Margin % | -2.34 | |||||
| ROE % | 12.22 | |||||
| ROA % | 8.44 | |||||
| ROIC % | 10.55 | |||||
| ROC (Joel Greenblatt) % | 20.5 | |||||
| ROCE % | 11.44 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.48 | |||||
| Forward PE Ratio | 20.81 | |||||
| PE Ratio without NRI | 25.45 | |||||
| Shiller PE Ratio | 26.26 | |||||
| Price-to-Owner-Earnings | 95.26 | |||||
| PEG Ratio | 42.42 | |||||
| PS Ratio | 5.5 | |||||
| PB Ratio | 2.98 | |||||
| Price-to-Tangible-Book | 3.24 | |||||
| Price-to-Operating-Cash-Flow | 22.76 | |||||
| EV-to-EBIT | 22.24 | |||||
| EV-to-EBITDA | 22.24 | |||||
| EV-to-Revenue | 5.81 | |||||
| EV-to-FCF | -250.04 | |||||
| Price-to-Projected-FCF | 3.9 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Price-to-Net-Current-Asset-Value | 15.61 | |||||
| Earnings Yield (Greenblatt) % | 4.5 | |||||
| FCF Yield % | -0.43 | |||||
| Forward Rate of Return (Yacktman) % | -3.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Weiguang Biological Products Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,167.172 | ||
| EPS (TTM) (Â¥) | 1.103 | ||
| Beta | 0.82 | ||
| Volatility % | 30.64 | ||
| 14-Day RSI | 43.98 | ||
| 14-Day ATR (Â¥) | 0.715718 | ||
| 20-Day SMA (Â¥) | 28.8915 | ||
| 12-1 Month Momentum % | -18.96 | ||
| 52-Week Range (Â¥) | 22.05 - 35.86 | ||
| Shares Outstanding (Mil) | 226.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Weiguang Biological Products Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Weiguang Biological Products Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen Weiguang Biological Products Co Ltd Frequently Asked Questions
What is Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880)'s stock price today?
The current price of SZSE:002880 is ¥28.10. The 52 week high of SZSE:002880 is ¥35.86 and 52 week low is ¥22.05.
When is next earnings date of Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880)?
The next earnings date of Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880) is .
Does Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880) pay dividends? If so, how much?
The Dividend Yield %  of Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880) is 0.71% (As of Today), Highest Dividend Payout Ratio of Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880) was 0.45. The lowest was 0.19. And the median was 0.21. The  Forward Dividend Yield % of Shenzhen Weiguang Biological Products Co Ltd(SZSE:002880) is 1.42%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers